Technical Analysis for AFMD - Affimed Therapeutics B.V.

Grade Last Price % Change Price Change
grade F 3.1 3.33% 0.10
AFMD closed up 3.33 percent on Friday, May 24, 2019, on 71 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical AFMD trend table...

Date Alert Name Type % Chg
New Downtrend Bearish 0.00%
Calm After Storm Range Contraction 0.00%
NR7 Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Calm After Storm Range Contraction 3.33%
Stochastic Reached Oversold Weakness 3.33%
Earnings Movers Other 3.33%
Inside Day Range Contraction 3.33%

Older signals for AFMD ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Affimed Therapeutics B.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate includes AFM13, a natural killer cell bispecific antibody (TandAb) that has completed a Phase I clinical trial for the treatment of certain CD30-positive (CD30+) B- and T-cell malignancies, including hodgkin lymphoma. The company's product candidates also comprise AFM11, a T-cell TandAb for the treatment of certain CD19+ B-cell malignancies, including non-hodgkin lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia; and AFM21, a TandAb program in preclinical development that binds epidermal growth factor receptor variant III for solid tumors, as well as for patients with glioblastoma, hormone refractory prostate cancer, and head and neck cancer. Affimed Therapeutics B.V. has license agreements with Amphivena Therapeutics, Inc. to develop a product candidate for hematologic malignancies; and Xoma Ireland Limited to conduct research on immunoglobulins. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
Medicine Biopharmaceutical Cancer Medical Specialties Solid Tumors Monoclonal Antibodies Lymphoma Glioblastoma Immunotherapies Chronic Lymphocytic Leukemia Hematologic Malignancies Seattle Genetics Head And Neck Cancer Non Hodgkin Lymphoma Tumors Of The Hematopoietic And Lymphoid Tissues Cd30 Hodgkin Lymphoma
Is AFMD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 7.35
52 Week Low 1.4
Average Volume 1,018,736
200-Day Moving Average 3.6314
50-Day Moving Average 3.698
20-Day Moving Average 3.387
10-Day Moving Average 3.295
Average True Range 0.1911
ADX 26.16
+DI 12.7076
-DI 31.1518
Chandelier Exit (Long, 3 ATRs ) 3.1367
Chandelier Exit (Short, 3 ATRs ) 3.4833
Upper Bollinger Band 3.7154
Lower Bollinger Band 3.0586
Percent B (%b) 0.06
BandWidth 19.391792
MACD Line -0.1343
MACD Signal Line -0.1034
MACD Histogram -0.0309
Fundamentals Value
Market Cap 136.21 Million
Num Shares 43.9 Million
EPS -0.99
Price-to-Earnings (P/E) Ratio -3.12
Price-to-Sales 22.02
Price-to-Book 1.82
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.29
Resistance 3 (R3) 3.28 3.19 3.26
Resistance 2 (R2) 3.19 3.14 3.20 3.25
Resistance 1 (R1) 3.15 3.11 3.17 3.16 3.24
Pivot Point 3.06 3.06 3.08 3.07 3.06
Support 1 (S1) 3.02 3.01 3.04 3.04 2.96
Support 2 (S2) 2.93 2.98 2.94 2.95
Support 3 (S3) 2.89 2.93 2.94
Support 4 (S4) 2.91